LILLY AND CO news, videos and press releases - Page 3
For more news please use our advanced search feature.
LILLY AND CO - More news...
LILLY AND CO - More news...
- Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement
- Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
- Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
- Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria
- Lilly Declares Third-Quarter 2024 Dividend
- Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
- Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
- Lilly announces departure of Anat Ashkenazi, chief financial officer
- Melissa Seymour to join Lilly as executive vice president of Global Quality
- Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
- Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases
- Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
- Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
- Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
- With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
- Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
- Lilly Declares Second-Quarter 2024 Dividend
- Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
- Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
- Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
- DoH Collaborates with Eli Lilly and World Obesity Federation on Obesity Prevention and Management
- Thinking about trading options or stock in Intuit, Pinterest, Adobe, Eli Lilly, or Robinhood Markets?
- More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
- Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care
- Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
- Lilly to Participate in Cowen's 44th Annual Health Care Conference
- Philip Johnson to Retire as Lilly Treasurer
- Thinking about buying stock in Foghorn Therapeutics, Oscar Health, Eli Lilly And Co, Palo Alto Networks, or CN ENERGY GROUP?
